Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Plc Regulatory News (EML)

Share Price Information for Emmerson Plc (EML)

Share Price is delayed by 15 minutes
Get Live Data
2.10    0.00 (0.00%)
Bid:
2.00
Ask:
2.20
Spread: 0.20 (10.00%)
Market Cap: £28.06m
EML Live PriceLast checked at - London Stock Exchange

Intraday Emmerson Plc Share Chart

Litigation Funding Secured

2 Jan 2025 07:00

RNS Number : 8324R
Emmerson PLC
02 January 2025
 

Emmerson Plc / Ticker: EML / Index: LSE / Sector: Mining

 

2 January 2025

Emmerson PLC

("Emmerson" or the "Company")

Litigation Funding Secured

and

Litigation Counsel Confirmed

Emmerson Plc, the Moroccan focused potash development company, is pleased to announce that it has signed a Capital Provision Agreement ("CPA") with a specialist litigation funding firm to provide up to US$11,000,000 in both litigation finance capital and working capital for the Company (the "Funding") and has confirmed Boies Schiller Flexner LLP ("BSF") as its litigation counsel. The Company has also put a Management Incentive Plan into place.

Litigation funding

The Funding shall primarily be used to progress the Company's dispute with the Government of the Kingdom of Morocco under the Agreement between the Government of the United Kingdom of Great Britain and Northern Ireland and the Government of the Kingdom of Morocco for the Promotion and Protection of Investments, which entered into force on 14 February 2002, being a Bilateral Investment Treaty (the "BIT").

Emmerson's CPA funding counterparty (the "Funding Party") is one of the world's largest and most successful litigation finance companies and a significant institution within the legal financing industry. The detailed terms of the CPA are confidential but, in summary:

· Up to US$11,000,000 can be drawn down in tranches, at the Company's request, to satisfy litigation funding requirements and for general working capital purposes;

· The Funding shall be provided on a non-recourse basis and the Funding Party shall receive no return if the arbitration claim is unsuccessful; and

· In the case of a successful settlement or award, the return to the Funding Party shall be based upon the greater of a multiple of the final drawn-down amount or a percentage of the final award.

The Company notes that it has obtained litigation funding for its potential arbitration proceedings under the BIT within two months from the original Notification of Dispute, a process that can typically take six to nine months, oftentimes longer. The Company is of the opinion that the Funding will provide the platform to provide the best long-term return for shareholders.

Litigation Counsel

The Company has confirmed the appointment of Boies Schiller Flexner LLP ("BSF") as its litigation counsel. BSF have a highly successful track record in similar BIT arbitration cases, including some recent high-profile awards. The funding is now in place for BSF to commence work in the New Year on our case.

Management Incentive Plan (MIP)

To retain the services of certain Directors and members of the Company's management team who are important to the Company's ongoing management and the progress of the litigation, and who have important historical information and knowledge to contribute towards the litigation, the Company has established a long-term Management Incentive Program (the "MIP"). The retention of the assistance of the Directors and member of the Company's management team for the litigation through the MIP will allow the Company to maintain its compliance with the terms of the CPA.

In line with recent litigation funding cases, the named members of the MIP will be entitled to 6%, in aggregate, of any monies awarded as damages to the Company ("Management Entitlement Amount") through arbitration or any other means, including early settlement.

After the final determination of each participant's entitlement to the Management Entitlement Amount, any remaining balance of the Management Entitlement Amount which has not been distributed to participants will be returned to the Company.

Graham Clarke, Managing Director of Emmerson PLC commented:

"The Company has undertaken a tremendous amount of work and effort in a short period of time to secure substantial financing from a reliable funding partner. This CPA secures the medium-term future of the Company and we can now move forward with BSF as our legal partners to deliver the best possible outcome for the Company and its shareholders. BSF tend to only take on winning cases and their confidence in the case reinforces our confidence in the outcome".

 

**ENDS**

For further information, please visit www.emmersonplc.com, follow us on Twitter (@emmerson_plc), or contact: 

 

Emmerson Plc

Graham Clarke / Hayden Locke

+44 (0) 207 138 3204

Panmure Liberum Limited (Nominated Adviser and Joint Broker)

Scott Mathieson / Will King

+44 (0) 20 3100 2000

Shard Capital Partners LLP (Joint Broker)

Damon Heath / Isabella Pierre

+44 (0) 207 186 9927

Notes to Editors

Emmerson has been focused on advancing the Khemisset project ("Khemisset" or the "Project") in Morocco into a low cost, high margin supplier of potash, and the first primary producer on the African continent. With an initial 19-year life of mine, the development of Khemisset is expected to deliver long-term investment and financial contributions to Morocco including the creation of permanent employment, taxation, and a plethora of ancillary benefits. As a UK-Moroccan partnership, the Company has been working towards significant international investment over the life of the mine.

Morocco is one of the leading phosphate producers globally and the development of this mine is set to consolidate its position as the most important fertiliser producer in Africa. The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K2O, with significant additional exploration potential, and is perfectly located to support the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. The need to feed the world's rapidly increasing population is driving demand for potash and Khemisset is well placed to benefit from the opportunities this presents. The Feasibility Study released in June 2020 indicated the Project has the potential to be among the lowest capital cost development stage potash projects in the world and also, as a result of its location, one of the highest margin projects. Updated financial estimates published in February 2024 indicated a net present value of US$2.2 billion, with an internal rate of return of approximately 40%.

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRUPUGAGUPAGQG
Date   Source Headline
30th Mar 20267:00 amRNSArbitration Memorial Submission
24th Mar 20267:00 amRNSResult of WRAP Retail Offer
20th Mar 20267:31 amRNSWRAP Retail Offer for up to £100,000
20th Mar 20267:30 amRNSResult of Placing and Subscription
20th Mar 20267:00 amRNSProposed Placing and Subscription
22nd Jan 20267:00 amRNSArbitration Update
26th Nov 20257:00 amRNSAppointment of Joint Broker
30th Sep 20257:00 amRNSInterim Results
24th Jul 202512:31 pmRNSResult of Annual General Meeting
1st Jul 20257:00 amRNSNotice of AGM
30th Jun 20253:36 pmRNS2024 Financial Results
1st May 20258:10 amRNSRequest for Arbitration
17th Mar 20257:00 amRNSLitigation Funding Update
13th Jan 20253:03 pmRNSAdditional Issuance of Shares and Rights
2nd Jan 20257:00 amRNSLitigation Funding Secured
12th Dec 20247:00 amRNSAdditional Issuance of Shares and Rights
6th Dec 20247:01 amRNSFundraising of £0.85 million
1st Nov 20247:00 amRNSNotice of dispute with Moroccan Government
28th Oct 20247:00 amRNSESIA Process, Board Changes, and Cash Management
14th Oct 20247:00 amRNSESIA Update
27th Sep 20247:00 amRNSInterim Results and Q3 Update
5th Jul 20247:00 amRNSQ2 Update
1st Jul 20247:00 amRNSChange of Nominated Advisor and Joint Broker
26th Jun 202411:33 amRNSResult of Annual General Meeting
31st May 202410:56 amRNSGrant of Share Options and PDMR dealing
31st May 20247:00 amRNSNotice of AGM and Posting of Annual Report
24th May 20247:00 amRNS2023 Financial Results
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor
21st Nov 20227:00 amRNSPotash and Salt Offtake MOUs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.